Global Plasma Fractionation Market

Plasma Fractionation Market size was valued at USD 32.96 Bn. in 2024, and the total Plasma Fractionation revenue is expected to grow at a CAGR of 6.89% from 2025 to 2032, reaching nearly USD 56.17 Bn.

Plasma Fractionation Market Overview

Plasma Fractionation Products are therapeutic proteins derived from human plasma through a separation process, including immunoglobulins (IVIG/SCIG), albumin, clotting factors (e.g., Factor VIII, IX), and protease inhibitors (e.g., alpha-1 antitrypsin). These life-saving treatments are used for immunodeficiency disorders, hemophilia, critical care, and chronic diseases. The market is driven by increasing demand, technological advancements, and expanding clinical applications.

The plasma fractionation market is experiencing strong demand for immunoglobulins and clotting factors; however, supply remains constrained due to limited donations and the lengthy processing time. Efforts to expand collection networks aim to bridge this gap.

North America dominates the plasma fractionation market, driven by advanced healthcare infrastructure and high plasma collection rates. Key players include CSL Behring (Australia), Grifols (Spain), and Takeda (Japan), which lead in immunoglobulin and albumin production. Their extensive plasma networks and R&D investments maintain industry leadership amid rising global demand.

The report focuses on the Plasma Fractionation Market value across the top regions and countries worldwide, highlighting regional developments, including market size, share, revenue, and more on a global scale. It covers capacity, production value, cost/profit, and supply/demand through statistical analysis. A brief analysis of market drivers, restraints, opportunities, and challenges is also included, with regional examples. To capitalize on opportunities, market vendors should focus more on growth prospects in fast-growing segments while maintaining their positions in slower-growing ones. The report also includes an analysis of key players' growth strategies, micro and macro market analyses, major developments, and emerging trends.To know about the Research Methodology   :- Request Free Sample Report

Plasma Fractionation Market Dynamics

Rising Prevalence of Chronic and Rare Diseases to Boost Plasma Fractionation Market Growth

The increasing incidence of immunodeficiency disorders, hemophilia, and neurological conditions is a major driver of the plasma fractionation market. Plasma-derived therapies, such as immunoglobulins (IVIG/SCIG), clotting factors, and albumin, are critical for treating these diseases. With aging populations and improved diagnostic capabilities, demand continues to surge. Additionally, the growing use of IVIG in autoimmune diseases (e.g., CIDP, lupus) and Alzheimer’s research further propels market growth. Pharmaceutical companies are expanding plasma collection and fractionation capacities to meet this rising demand, ensuring a steady supply of life-saving therapies.

High Costs and Complex Manufacturing Processes to Restrain the Plasma Fractionation Market

Plasma fractionation is capital-intensive, requiring specialized facilities, stringent regulatory compliance, and costly pathogen safety measures. The long production cycle (7-12 months) and limited plasma supply create bottlenecks, leading to high treatment costs for end-users. Reimbursement challenges in emerging markets further restrict patient access. Additionally, strict donor eligibility criteria and logistical hurdles in plasma collection hinder scalability, making it difficult for smaller players to compete with established fractionators like CSL Behring and Grifols.

Expansion in Emerging Markets and Development of Novel Plasma-Based Therapies to Create Opportunity for the Plasma Fractionation Market

Emerging economies (China, India, Brazil) present significant growth opportunities due to increasing healthcare investments, rising awareness of plasma therapies, and government initiatives to boost local fractionation capabilities. Additionally, advancements in recombinant alternatives and hyperimmune globulins for infectious diseases (e.g., Zika, Ebola) open new revenue streams. The growing use of plasma proteins in regenerative medicine and oncology further expands the market. Strategic partnerships and contract fractionation services offer additional avenues for growth, particularly for biotech firms entering the space.

Plasma Fractionation Market Segment Analysis

Based on Type, the Plasma Fractionation Market is segmented into Immunoglobulins, Coagulation Factor Concentrates, Albumin, Protease Inhibitors, and Other. The immunoglobulin segment dominated the Plasma Fractionation Market in 2024 and is expected to hold the largest market share over the forecast period. Dominance due to their broad therapeutic applications in treating immunodeficiency disorders, autoimmune diseases (e.g., CIDP, lupus), and neurological conditions, alongside increasing off-label use in Alzheimer’s and long COVID research.

The segment benefits from rising demand in aging populations and advancements in subcutaneous (SCIG) and high-concentration IVIG formulations. While coagulation factors remain critical for hemophilia treatment, they face competition from recombinant alternatives, and albumin demand stays steady but is limited by synthetic substitutes. Protease inhibitors, though niche, show growth in COPD and genetic emphysema, but immunoglobulins continue leading the market with expanding clinical indications and irreplaceable therapeutic value.

Based on End-User, the Plasma Fractionation Market is segmented into Hospitals & Clinics, Clinical Research Laboratories, Academic Institutions, and Others. The Hospitals & Clinics segment dominated the Plasma Fractionation Market in 2024 and is expected to hold the largest market share over the forecast period. Dominance by the high demand for plasma-derived therapies (e.g., IVIG, albumin, clotting factors) in critical care, surgeries, and chronic disease management. Their widespread infrastructure, ability to administer complex treatments, and strong reimbursement systems solidify their dominance. Clinical research laboratories follow, fueled by growing R&D in plasma-based therapies, while academic institutions contribute through specialized studies. However, hospitals remain the primary segment due to direct patient care needs and rising hospitalization rates for conditions requiring plasma products, such as immunodeficiencies, hemophilia, and trauma cases.

Plasma Fractionation Market Regional Analysis

North America dominated the plasma fractionation market in 2024

The largest revenue shares are due to your well-established healthcare infrastructure, high adoption of plasma-practical remedies, and strong plasma collection networks. North America leads the region, which is supported by chronic diseases (eg, haemophilia, PIDD), favorable reimbursement policies, and the presence of major industry players such as CSL Behring, Grifols, and Takeda. Additionally, increasing investment in plasma donation centers and advanced calibration technologies further strengthens the dominance of North America.

Europe follows closely, inspired by the growing demand of the government promoting immunoglobulin and albumin, stringent regulatory standards, and plasma remedies. Meanwhile, the Asia-Pacific region is the fastest-growing market, which improves healthcare access, expands plasma collection programs, and increases awareness about plasma-excellent treatments in countries such as China and India. However, North America is at the forefront of its mature market dynamics and strong clinical adoption of plasma products.

Plasma Fractionation Market Competitive Landscape

CSL Behring is aiming to generate $ 16-17 billion in revenue operating from the strong sales of immunoglobulin (Privigen, Hizentra), Hemophilia Therapy (including gene therapy hemgenics), and albumin, strategic pricing, and emerging market expansion. Grifols, the second largest player, expects $ 6.5–7 billion in revenue, supported by major products such as its major plasma collection network (300+ centers) and IVIG (Gammagard) and albumin (Flexbumin), although it faces financial movement challenges. For comparison, Takeda's plasma-reputed therapy revenue is estimated $ 4–5 billion, which is behind these two giants. The revenue of CSL is around 2.5 times that Grifols, reflecting its diverse biotech portfolio (including vaccine and gene therapy), while Grifols remains a pure-play plasma expert. Both companies rely a lot on the U.S.-Sound plasma (60-70% supply) and continue investing in the next-generation calibration technologies and pathogen safety to maintain market dominance.

Plasma Fractionation Market Recent Development

Plasma Fractionation Industry Ecosystem: -

Plasma Fractionation Market Scope: Inquire before buying

Plasma Fractionation Market Key Region

North America (United States, Canada and Mexico)
Europe (United Kingdom, France, Germany, Italy, Spain, Sweden, Russia, Rest of Europe)
Asia Pacific (China, Japan, South Korea, India, Australia, Malaysia, Thailand, Vietnam, Indonesia, Philippines, Rest of APAC)
Middle East and Africa (South Africa, GCC, Nigeria, Egypt, Turkey, Rest of MEA)
South America (Brazil, Argentina, Colombia, Chile, Peru, Rest of South America)

Plasma Fractionation Market Key Players are:

North America
1. CSL Plasma (USA - subsidiary of Australia's CSL Behring)
2. ADMA Biologics (USA)
3. Emergent BioSolutions (USA)

Europe
1. Grifols (Spain)
2. Octapharma (Switzerland)
3. Kedrion (Italy)
4. Biotest (Germany)https://www.grifols.com/en/home
5. LFB Group (France)
6. Sanquin (Netherlands)

Asia Pacific
1. China Biologic Products (CBPO) (China)
2. Hualan Biological Engineering (China)
3. Shanghai RAAS Blood Products (China)
4. Tiantan Biological Products (China)
5. Takeda (Japan)
6. Japan Blood Products Organization (JPBO) (Japan
7. Green Cross Corporation (South Korea)
8. SK Plasma (South Korea)
9. Reliance Life Sciences (India)
10. Bharat Serums and Vaccines (India)

Middle East and Africa
1. GCC Biotech (Saudi Arabia)
2. National Bioproducts Institute (NBI) (South Africa)
3. Kedrion Middle East (UAE - subsidiary of Italy's Kedrion)
4. Octapharma Middle East (UAE - subsidiary of Switzerland's Octapharma)

South America
1. Hemobras (Brazil)
2. Instituto Grifols (Brazil - subsidiary of Spain's Grifols)
3. Biofarma (Brazil)

Frequently Asked Questions:

1. Which region has the largest share in the Global Market?
Ans: The North America region held the highest share in 2024.

2. What is the growth rate of the Global Market?
Ans: The Global Market is growing at a CAGR of 6.89% during the forecasting period 2025-2032.

3. What is the scope of the Global Market report?
Ans: Global Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.

4. What is the study period of this Market?
Ans: The Global Market is studied from 2025 to 2032.